IHAM
SNDX icon

Integral Health Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Integral Health Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.18M Buy
350,000
+150,000
+75% +$3.26M 0.39% 67
2025
Q4 		$4.2M Buy
+200,000
New +$3.49M 0.21% 73

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Integral Health Asset Management's SNDX Position: Q1 2026 in Review

Integral Health Asset Management increased its Syndax Pharmaceuticals (SNDX) stake by 75% in Q1 2026, buying an estimated $3.26M and bringing the position to 350,000 shares worth $8.18M. The position accounts for 0.39% of the portfolio, ranked #67.

Integral Health Asset Management first reported a position in SNDX in Q4 2025 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Integral Health Asset Management held 350,000 shares of Syndax Pharmaceuticals worth $8.18M as of Q1 2026.
  • Integral Health Asset Management bought 150,000 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.26M.
  • Syndax Pharmaceuticals made up 0.39% of Integral Health Asset Management's portfolio in Q1 2026, its #67 holding.
  • Integral Health Asset Management first reported a position in Syndax Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.